JUL 01, 2020 10:00 AM PDT

The right diagnosis for every person: Polyvalent, high throughput molecular platforms for early case finding and prompt treatment of TB and DR-TB in the era of COVID-19

Sponsored by: Abbott Molecular
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa, Ethiopia
    Biography
      Dr. Manyazewal has extensive experiences and an expert in infectious diseases management and public health policy, especially in the fight to end tuberculosis. He has authored and co-authored over 47 publications. Dr. Manyazewal has worked at University of California San Diego, Mayo Clinic, University of Maryland School of Medicine and Johns Hopkins University US PEPFAR programs in Ethiopia.
    • Clinical Microbiologist/Immunologist - Muhimbili University of Health and Allied Sciences, Tanzania
      Biography
        Dr. Majigo has extensive experience in health related activities including research, capacity building, program implementation and laboratory management through working with national and international organizations. He serves as consultant for Antimicrobial Resistance (AMR) surveillance in Tanzania. He was instrumental in development of the National Antimicrobial Resistance Action Plan and AMR Surveillance Framework. He participates in activities coordinated by the Department of Microbiology and Immunology including, teaching, research, consultancy and provision of public service. Dr. Majigo has been involved in several studies of infectious disease specifically HIV, TB, sexually transmitted disease, Rubella, and bacterial infection.

      Abstract

      DATE: July 1, 2020

      TIME:  10:00am PT

       

      Moving forward to the 2035 global END TB targets, access to accurate TB and DR-TB diagnostic tools are needed more than ever before. As a direct consequence of COVID-19, an additional 6.3 million new TB cases and 1.4 million deaths are estimated between 2020 and 2025, and high-burden countries will remain on top. There is a strong need to enhance the capacity for accurate diagnosis of TB and DR-TB as people ill with COVID-19 and TB show similar symptoms. Major progress has been made for rapid and accurate diagnosis of TB and DR-TB using real-time, molecular assays and this could harness TB case findings in the COVID-19 outbreak.

      This webinar intends to exchange views on the role and contributions of polyvalent, high throughput molecular platforms in early case finding and prompt treatment of TB and DR-TB. It consists of three areas of focus: the current diagnostic algorithm for TB and DR-TB in high-burden countries; the need for laboratory capacity for DR-TB and impact on population; and the power of polyvalent diagnostic platforms to address TB and DR-TB case findings in the COVID-19 outbreak.

       

      Learning Objectives:

      • Understand current testing and platform challenges of MTB and RIF/INH 

      • Understand the clinical utility of mTB and RIF/INH resistance testing in managing mTB patients

      • Understand the workflow process to implement mTB testing in areas that need scale up and automation 
         

       

      Webinars will be available for unlimited on-demand viewing after live event.

       

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


      Show Resources
      Show Resources
      Attendees
      • See more
      Connect with us